(INNPF) – Press Releases
-
Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million
-
Innocan Pharma Reports Successful Results of Efficacy Test for Vaginal Derma Product
-
Innocan Pharma Announces Launch of CBD Veterinary Commercialization Team
-
Innocan Pharma Announces First Patent Grant in the United States
-
Innocan Pharma Reports Clinical Success in Canine Compassionate Care Trial
-
Innocan Pharma Provides Annual "State of the Business" Update
-
Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field
-
Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021
-
Mr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee
-
Innocan Pharma Goes Live with Priority(TM) ERP System
-
Innocan Pharma to Participate in IR Labs' Investor Webinar on November 2, 2022
-
Innocan Pharma to Participate in the Luxury Meets CBD Conference on October 20 & 21 in New York
-
Innocan Pharma's Patent Application for Treatment of Psoriasis of the Scalp Reached National Phase
-
Innocan Pharma Provides an Operational Update
-
Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment
-
Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
-
Innocan Pharma Announces Q2 2022 Results with 70% Annual Increase in Cash Balance and 70% Increase in Working Capital
-
Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology
-
Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform
-
Innocan Pharma Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss
-
Innocan Pharma Files PCT Patent Application for Diabetic Symptoms
-
Former Dexcel Pharma Analytical Chemist to Join Innocan Pharma LPT Pharmaceutical R&D Team as it is Moving Forward with the LPT Development
-
Innocan Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures On a Dog using LPT: "Since The Last LPT injection, Paco (dog) Has Not Had a Seizure for Over 10 weeks"
-
Innocan Reports Successful Preclinical Dog-Trial Results Regarding Pain Management: "It Was as If a New Dog Came into Our Lives"
-
Innocan Pharma Announces Filing of PCT Patent Application for Vaginal Atrophy Treatment
-
Innocan Reports Successful Preliminary Trial Results Regarding Epilepsy in Dogs
-
Innocan Pharma Announces Q1 2022 Results with 215% Increase in Cash Balance and 200% Increase in Working Capital
-
Innocan Pharma Obtains Receipt for Final Base Shelf Prospectus
-
Innocan Pharma Announces the Successful Publication of a New Patent Application of Its New Sustained-Release (LPC) CBD Formulation
-
Innocan Pharma's Compassionate Care Treatment for Dogs
-
Innocan Pharma's Case Report Accepted to the 25M Readers of Frontiers Veterinary Scientific Journal
-
Innocan Pharma Reports a Positive Result from the Use of Its CBD LPT on a Dog Suffering from Osteoarthritis
-
Former Beckman Coulter Dr. Eyal Kalo to join Innocan Pharma's Expanding R&D Team
-
Sony Ex-VP Dr. Kenji Kitatani to Join Innocan Pharma's Advisory Committee
-
Cannabis Industry Investor Presentations Now Available for On-Demand Viewing
-
Innocan Pharma Announces Important Updates Regarding its LPT Platform Project and Commercialization Paths
-
Cannabis Industry Investor Conference: Company Executives Present January 19th & 20th
-
Innocan Pharma Announces the Inauguration of Its Drug Development Lab at Biohouse in the Hadassah Medical Center in Jerusalem
-
Innocan Pharma to Expand its LPT Platform to the Veterinary Field
-
Innocan Announces the Execution of a Research & License Agreement with Ramot, the Technology Transfer Company of the Tel Aviv University for Cannabinoids Loaded Exosome Delivery Platform (CLX)
-
Innocan Pharma Announces the Successful Demonstration of Prolonged Release of CDB in Dogs Using Its LPT Technology
-
Innocan Pharma to Participate in the Lift & Co. Expo's Business Growth Panel on November 19th, 2021
-
Innocan Pharma Reports Further Success in Profile Characterization Progress In Its micro-RNA Cannabinoids Loaded Exosome Delivery Platform (CLX) Project
-
Innocan Pharma Announces 100% Exercise of Warrants Issued in December 2020 Private Placement
-
Innocan Pharma CEO Iris Bincovich to Deliver a Speech at an Investor Gathering in Munich on October 29, 2021
-
Innocan Reports of Presence of CBD in Mice's Brains 41 Days After Injection of CBD Using Innocan's Liposome Platform Technology
-
Innocan Pharma Corporation Closes C$8.2 Million Private Placement with Institutional Investors
-
Innocan Pharma Corporation Announces C$8.2 Million Private Placement with Institutional Investors
-
Innocan Pharma Announces the Filing of a PCT Patent Application for its CBD Delivery System Technology in 153 Countries
-
Innocan Pharma Announces the Filing by Ramot at Tel Aviv University of an International Patent Application for its Unique Cannabinoids Loaded Exosome Delivery Platform (CLX)
Back to INNPF Stock Lookup
